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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Calling it “tough news to share” and “even more difficult to
receive,” pharmaceutical giant Roche announced on March 22 that
it has halted dosing in the firm’s historic Phase 3 Huntington's
disease clinical trial of its gene silencing drug tominersen,
GENERATION HD1, because of unfavorable efficacy data, as
seen by an independent review committee.
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“The committee recently met for a pre-planned review of the latest
safety and efficacy data from GENERATION HD1 and made a
recommendation about the investigational therapy’s potential
benefit/risk profile,” wrote David West, Roche’s senior director,
for Global Patient Partnership, in a letter addressed to the
international HD community. “Based on the committee’s
recommendation, we will permanently stop dosing with
tominersen and placebo in the GENERATION HD1 study.”
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GENERATION HD1 began in early 2019, paused for several
months to recalibrate dosing, and became fully enrolled in April
2020. Volunteers were to receive the drug over 25 months, and
Roche had expected to finish the trial and report results in 2022.
Tominersen developer Ionis Pharmaceuticals, Inc., Roche’s
partner, had completed a Phase 1/2a trial of the drug (testing for
mainly safety and tolerability) in 2017. That trial was so successful
that Roche skipped a full-blown Phase 2 and went directly to
Phase 3, GENERATION HD1.
West noted that the review committee’s recommendations resulted
not from “any new emergent safety concern, but on a broad
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assessment of the benefit/risk” for those receiving the drug as
compared to those getting the placebo.
This means that the drug demonstrated an “unfavorable efficacy
trend,” an official of U.S. Roche’s subsidiary Genentech wrote me
in an e-mail. If successful, the trial would have demonstrated that
tominersen could slow, halt, or even reverse HD symptoms.
“This is brutal and I am absolutely devastated for our patients and
families,” Jody Corey-Bloom, M.D., Ph.D., the director of the
Huntington’s Disease Society of America (HDSA) Center of
Excellence at the University of California, San Diego, wrote me.
Trial participants in Dr. Corey-Bloom’s clinic were among those
taking part in GENERATION HD1. “I am glad that Roche will
continue following patients for safety and clinical outcomes,” she
added.
Veteran HD physician LaVonne Goodman expressed a similar
sentiment. “Hope has been so very high for this drug; our
community will feel not just disappointment, but real grief,” Dr.
Goodman wrote me. “However, we’re accustomed to grief, and are
resilient. I think part of the community message should be that
supporting each other is vitally important now.”
HDSA Chief Scientific Officer George Yohrling, Ph.D., called the
news “devastating.” “HD families around the world had their
hopes held high that this experimental drug could one day soon
become an effective therapy for HD,” Dr. Yohrling stated. “While
this is clearly not the news we wanted to hear, I am confident that
in the coming weeks the Generation HD1 data will help the
scientific community understand why tominersen did not meet its
desired outcome.”
Robert Pacifici, Ph.D., the chief scientific officer for CHDI
Foundation, Inc., the nonprofit virtual biotech dedicated to
discovering HD therapies and a collaborator of Roche and Ionis,
also commented on the development.
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“Roche’s decision to discontinue dosing in most of its
Huntington’s disease studies based on a recommendation from the
unblinded [with access to data] Independent Data Monitoring
Committee that periodically reviews study data is a very
disappointing outcome,” Dr. Pacifici wrote. “However, knowing
our colleagues at Roche we are confident that this decision has
been made in good faith with the best interests of study
participants uppermost in mind.”

No new safety concern caused the halt
The stop to the Roche trial underscores the fact that an effective
treatment still eludes not only HD scientists, but also researchers
of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral
sclerosis (ALS), and other neurological conditions.
The reviewers who recommended the halt to GENERATION HD1
work separately from Roche. The committee has not yet shared its
specific reasoning or data with Roche.
“It is important to note that the recommendation is not based on
any new emergent safety concern,” West’s letter stated.
Roche has notified the clinical trial sites in the 18 participating
countries of the halt. The sites are contacting the 791 symptomatic
volunteers who had enrolled in the program.
The participants were receiving intrathecal (spinal) injections of
tominersen or a placebo. Participants in GEN-EXTEND (an
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extension study for participants coming from any Roche HD
study) will also no longer receive doses.
“It is our intention to provide as much information as we can to the
community, which at this time is limited until we have accessed
and analyzed full data,” West’s letter explained.
West acknowledged “the tremendous contribution of the families
who are participating in these studies, as well as the broader
Huntington’s community for their collaboration.”
Next steps depend on the data
Although Roche has stopped giving tominersen to the volunteers,
the trial has not yet ended.
“The studies will remain ongoing (without further dosing in
GENERATION HD1 and GEN-EXTEND) and it is intended that
study participants will be followed by their physicians for safety
and clinical outcomes,” West stated. Roche has not provided a
timeline for the remainder of the work to be completed.
A Q&A appended to West’s letter states that “Roche remains
committed to the HD space and our studies are continuing,” and
data from GENERATION HD1 “will advance our understanding
of tominersen and inform research for other disease modifying
treatments.” It adds: “In addition to tominersen, the Roche family
of companies is investigating gene therapy approaches to treating
Huntington’s disease.”
The conclusions about GENERATION HD1 – and possible next
steps by Roche and Ionis– will depend on the analysis of the
independent reviewers’ explanations and all of the massive data
from the Phase 3 trial.
As Dr. Pacifici noted, only when data from the independent review
committee has been “shared with the wider HD community” will it
become possible to “form a scientific opinion” about the halting of
the trial.
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A perplexing result
Ionis held a public conference call on March 22 to answer
questions about the Roche announcement.
“This is the largest Huntington’s trial ever conducted,” stated Ionis
CEO Brett Monia, Ph.D. “It was conducted on a wealth of
information.”
Monia stated that, “while we are saddened by today’s outcome, we
are committed to the HD community and focused on delivering
treatments for this and other devastating neurological diseases.”
Monia added, “Although this is a disappointing setback for Ionis
and the HD community, we are confident in the potential of our
technology platform to address many neurological diseases.”
Various questioners on the call asked Dr. Monia and Ionis
scientists to speculate about the reasons for the halt and future
potential approaches using the company’s technology (antisense
oligonucleotides, or ASOs), but the Ionis officials emphasized that
answers are premature without access to the data.
“We are still strong believers in the ASO approach,” Dr. Monia
asserted.
However, Ionis Chief Scientific Officer Frank Bennett, Ph.D., the
long-time coordinator of the firm’s HD program, added that the
news of the potential ineffectiveness of using an ASO to reduce
the amount of huntingtin protein in patients was “perplexing and
disappointing to us,” leaving many unanswered questions.
Eric Swayze, Ph.D., Ionis’s executive vice president for research
and one of the developers of the ASO, reminded the participants
on the call of a fundamental reality of HD: “It’s a complex
disease.”
Dr. Monia added that “one silver lining” in the halt to
GENERATION HD1 was that it did not, as noted above, result
from a concern about safety.
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Diversification necessary
Although the pioneering Roche-Ionis program had electrified the
HD world with the hope of the first effective treatment, the HD
research community has also deliberately diversified the
approaches to treating HD.
Thus, companies like Triplet Therapeutics, Inc. have leveraged
publicly available knowledge gained from the Roche/Ionis
program and others to plan their own, unique drug development
strategies.
Triplet aims to start a clinical trial in the second half of this year
for a potential drug targeted at stopping the mutant huntingtin
gene’s tendency for continued expansion with age. That expansion
compromises brain cells and triggers disease. In this respect, HD is
known as a repeat expansion disorder (RED), with the triplets of
the genetic code CAG recurring too many times and thus causing
disease.
As a Triplet scientist explained last year, the Roche/Ionis approach
is like “putting a brake” on the disease, whereas Triplet’s ASO will
target the expansion of the gene and therefore seek to “remove the
foot on the gas.” (Click here to read more).
Using the same mechanism, in addition to HD, Triplet hopes to
develop transformative treatments for many of the more than 50
other REDs. For REDs of the central nervous system, it would use
the same drug as for Huntington’s.
Although unavailable for comment on the Roche announcement,
Triplet executives offered encouragement in an e-mail to me:
“Triplet’s thoughts are with the HD community, and our clinical
development plans in HD and other repeat expansion disorders
remain on track and unchanged.”
As one scientist wrote me (and as I also felt), the Roche
announcement was like a punch to the gut. However, I am also
heartened by the potential of other clinical trials like Triplet’s. (I
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will further explore the implications of the Roche trial halt in
upcoming articles.)
To echo Dr. Goodman’s words, our community and its scientists
are indeed resilient.
(For more on the Roche announcement, see the article in
HDBuzz).
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 4:34 PM
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